Literature review of conjunctivitis, conjunctival swab and chloroquine effect in the eyes: a current updates on COVID-19 and ophthalmology

https://doi.org/10.19106/JMedSciSI005203202003

Indra Tri Mahayana(1*), Natalia Christina Angsana(2), Alya Kamila(3), Nisrina Nur Fatiha(4), Devin Zen Sunjaya(5), Winanto Andajana(6), Suhardjo Suhardjo(7)

(1) Department of Ophthalmology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(2) Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(3) Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(4) Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(5) Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(6) Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(7) Department of Ophthalmology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(*) Corresponding Author

Abstract


This overview briefly describes current literature findings in ophthalmology related to coronavirus disease 2019 (COVID-19) that become a worldwide pandemic. It included the current updates related to conjunctivitis that believed as the early sign of COVID-19, the effectiveness of conjunctival swab in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to naso- or oropharyngeal swab and the long-term side effect of chloroquine use to the eyes. The analysis from four current published literatures revealed, overall sensitivity of conjunctivitis was 2.42% (CI 95%: 0.79-5.55) and conjunctival swab was 2.90% (CI 95%: 1.07-6.20). There were no current COVID-19-related literatures discussing the side effect of chloroquine to the eyes, however, previous literatures revealed there were potential long-term harmful effects of chloroquine treatment to the eyes.

 


Keywords


conjunctiva; coronavirus; COVID-19; ocular; chloroquine;

Full Text:

PDF


References

  1. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol 2020; 92(6):589-94. https://doi.org/10.1002/jmv.25725
  2. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708-20. https://doi.org/10.1056/ NEJMoa2002032
  3. Chen L, Liu M, Zhang Z, Qiao K, Huang T, Chen M, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Brit J Ophthalmol 2020; 104(6):748-51 https://doi.org/10.1136/bjophthalmol-2020-316304
  4. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019. (COVID-19). Can J Ophthalmol 2020; S0008-4182(20):30305-7. https://doi.org/10.1016/j.jcjo.2020.03.003
  5. Zhou Y, Zeng Y, Tong Y, Chen C. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva. Med Rxiv 2020. https://doi.org/10.1101/2020.02.11.20021956
  6. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020; 138(5):575-8. https://doi.org/10.1001/jamaophthalmol.2020.1291
  7. Deng C, Yang Y, Chen H, Chen W, Chen Z, Ma K, et al. Ocular detection of SARS-CoV-2 in 114 Cases of COVID-19 pneumonia in Wuhan, China: an observational study 2020. https://doi.org/10.2139/ssrn.3543587
  8. Sun Y, Liu L, Pan X, Jing M. Mechanism of the action between the SARS-CoV S240 protein and the ACE2 receptor in eyes. Int J Ophthalmol 2006; 6:783-6.
  9. Peng Y, Zhou Y. Is novel coronavirus disease (COVID-19) transmitted through conjunctiva? J Med Virol 2020; 1-2. https://doi.org/:10.1002/jmv.25753
  10. Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf 2020; 18(3):360-2. https://doi.org/10.1016/j.jtos.2020.03.010
  11. Chan W. Tears and conjunctival scrapings for coronavirus in patients with SARS. Br J Ophthalmol 2004; 88(7):968-9. https://doi.org/10.1136/bjo.2003.039461
  12. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 2020; 395(10224):e39. https://doi.org/10.1016/S0140-6736(20)30313-5
  13. Cascella M, Rajnik M, Cuomo A, Dulebon SC, di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Stat Pearls [Online]. Treasure Island (FL): Stat Pearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776
  14. Devaux CA, Rolain J, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob 2020; 55(2020):105938 https://doi.org/10.1016/j.ijantimicag.2020.105938
  15. Frie K, Gbinigie K. Chloroquine and hydroxychloroquine: current evidence for their effectiveness in treating COVID-19. Oxford COVID-19 Evidence Service, Center for Evidennce-Base Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, 2020.
  16. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
  17. Iselin KC, Marti P, Pless M. Hydroxychloroquine-induced retinal toxicity. Klin Monbl Augenheilkd 2016; 233(04):1514-6. https://doi.org/10.1055/s-0042-102615
  18. Alshaban F. A recommendation for the use of chloroquine, hydroxychloroquine, primaquine or tefanoquine for prophylaxis against the 2019 novel coronavirus (COVID-19) with note to the ophthalmic considerations. Eye Reports 2020; 6(1). https://www.eyereports.org/index.php/eyereports/article/view/99/PDF Eye Reports 2020 v6pS7
  19. Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Opthalmology 2016; 123(6):1386-94. https://doi.org/10.1016/j.ophtha.2016.01.058
  20. Ruamviboonsuk P, Lai TYY, Chang A, Lai CC, Mieler WF, Lam DSC. Chloroquine and hydroxychloroquine retinal toxicity consideration in the treatment of COVID-19. Asia Pac J Ophthalmol (Phila)2020; 9(2):85-7. http://doi.org/10.1097/APO.0000000000000289
  21. Yusuf IH, Foot B, Galloway J, Arden-Jones MR, Watson SL, Yelf C, et al. The royal college of ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary consensus-statement. Eye (Lond)2018; 32(7):1168-73. https://doi.org/10.1038/s41433-018-0136-x



DOI: https://doi.org/10.19106/JMedSciSI005203202003

Article Metrics

Abstract views : 3582 | views : 6201


Bookmark and Share


Copyright (c) 2020 Indra Tri Mahayana, Natalia Christina Angsana, Alya Kamila, Nisrina Nur Fatiha, Devin Zen Sunjaya, Winanto Andajana, Suhardjo Suhardjo

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

FUJI188